Saturday 17 October 2026
Export PPCB’s income statement to Excel — free account
Propanc Biopharma Inc
PPCB Healthcare Biotechnology
In the quarter to June 2026, EPS fell 99.6%, free cash flow fell 1,637.4% and total debt fell 21.4%, each against the same quarter a year earlier.
0.34
0.00
0.00%
Follow PPCB
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
2.55 | 1.50 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 |
Net Debt/EBITDA |
0.02 | (0.01) | (0.20) | (0.06) | (0.02) | (0.03) | 0.00 | (0.02) | (0.01) | 0.00 |
Debt/Assets |
3.61% | 2.99% | 448.62% | 190.05% | 62.67% | 423.66% | 51.78% | 51.03% | 76.75% | 62.15% |
Debt/Equity |
0.05 | 0.04 | (0.09) | (0.04) | (0.02) | (0.02) | (0.01) | (0.01) | (0.01) | (0.01) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.29 | 0.01 | 0.46 | 0.35 | 0.43 | 0.47 | 0.39 | 0.36 | 0.31 | 0.26 |
Capex/Depreciation |
(4.90) | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.26) | 0.00 | 0.00 |
Interest Coverage |
(42.24) | (101.59) | (2.31) | (3.33) | (3.50) | (4.03) | (2.00) | (1.99) | (1.42) | (1.79) |
| (169.86%) | (1,163.68%) | 58.39% | 101.75% | 110.09% | 71.97% | 119.22% | 104.10% | 115.36% | 196.27% | |
| (122.15%) | (598.08%) | (3,034.66%) | (4,403.94%) | (7,085.23%) | (4,332.80%) | (4,735.96%) | (6,653.26%) | (8,455.50%) | (3,318.22%) | |
ROIC |
(125.86%) | (247.22%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(381.25%) | (2,123.67%) | 53.09% | 99.61% | 110.26% | 78.76% | 129.34% | 133.81% | 104.22% | 144.52% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | — | — | 0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% |
Free Cash Flow per Share |
(5.06) | (2.55) | (9,351.00) | (0.64) | (21.06) | (0.38) | (75.19) | (3.93) | (55.27) | (0.58) |
Cash per Share |
0.74 | 0.08 | 211.00 | 0.01 | 0.06 | 0.00 | 2.72 | 0.00 | 0.51 | 0.02 |
Shareholders Equity per Share |
8.37 | 87.63 | (37,791.00) | (1.79) | (44.33) | (1.01) | (148.02) | (8.19) | (171.37) | (1.55) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
8.37 | 87.63 | (37,791.00) | (1.79) | (44.33) | (1.01) | (148.02) | (8.19) | (171.37) | (1.55) |
Free Cash Flow |
(5.69) | (0.41) | (0.94) | (1.11) | (1.44) | (1.15) | (1.85) | (2.06) | (2.18) | (2.05) |
Working Capital |
5.19 | 2.77 | (3.77) | (3.14) | (3.05) | (3.07) | (3.67) | (4.31) | (6.76) | (5.45) |
Capital Expenditures |
0.00 | — | — | — | — | — | — | 0.00 | — | — |
Net Current Asset Value |
5.16 | 2.63 | (3.83) | (3.16) | (3.09) | (3.07) | (3.67) | (4.31) | (6.76) | (5.45) |
| Other line items | ||||||||||
Quick Ratio |
0.25 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.01 |
Depreciation/Fixed assets |
0.26 | — | (0.01) | 5.67 | 1.00 | 0.47 | 0.44 | 0.27 | 0.27 | 0.20 |
Cash ROIC |
(53.18%) | (2.79%) | 27.24% | 36.93% | 48.39% | 38.05% | 52.49% | 48.57% | 32.61% | 38.59% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(5.06) | (2.55) | (9,351.00) | (0.64) | (21.06) | (0.38) | (75.19) | (3.92) | (55.27) | (0.58) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 |
Average Receivables |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 |
Average Payables |
1.19 | 1.23 | 1.09 | 0.95 | 0.97 | 0.92 | 0.88 | 1.04 | 0.82 | 0.43 |
Average Assets |
16.21 | 9.85 | 0.07 | 0.07 | 0.05 | 0.06 | 0.10 | 0.09 | 0.08 | 0.24 |
Average Common Equity |
11.65 | 5.06 | (3.45) | (3.07) | (3.05) | (3.36) | (3.98) | (5.53) | (6.10) | (4.01) |
Capex to Sales |
0.00 | — | — | — | — | — | — | 0.00 | — | — |
Columns are period end dates · fundamentals updated 6 Oct 2026